Physician profile
Nancy C Lank
NPI 1356317127
$8,744.97
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,922 · 2020: $1,787 · 2021: $36.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $8,020.00 | 2019-2020 | |
| Allergan, INC. | $189.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.82 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $61.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $51.93 | 2019 | |
| Jazz Pharmaceuticals INC. | $49.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.03 | 2019-2020 | |
| Novo Nordisk INC | $39.41 | 2019-2020 | |
| Neos Therapeutics, LP | $38.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $31.56 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.78 | 2021 | |
| Amgen INC. | $15.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.15 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.81 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.55 | 2019 | |
| Glaxosmithkline, LLC. | $13.11 | 2019 | |
| Genentech USA, INC. | $12.86 | 2019 | |
| Pfizer INC. | $11.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Lank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.